Can Fusion Proteins be Targeted for Cancer Treatment?
Yes, fusion proteins can be targeted for cancer treatment. The development of targeted therapies has been a major advancement in cancer treatment. Drugs like Imatinib (Gleevec) specifically inhibit the BCR-ABL fusion protein, providing significant clinical benefits for patients with CML. These targeted therapies are designed to specifically inhibit the activity of fusion proteins, thereby reducing cancer cell proliferation and survival while sparing normal cells.